Related Experiment Video
Updated: Feb 8, 2026

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
Published on: April 14, 2016
[Biological aspects and clinical application of bone-marrow stem cells in critical lower limb ischaemia]
P Iu Orekhov1, A V Troitskiĭ1, A V Chupin1
1Vascular Surgery Department, Federal Scientific Clinical Centre of Specialized Types of Medical Care and Medical Technologies under the Federal Biomedical Agency of Russia, Moscow, Russia.
Insights
Critical lower-limb ischaemia (CLLI) treatment shows promise with cell therapy (CT) using bone marrow stem cells (BMSCs). This review explores BMSCs
Area of Science:
- Regenerative Medicine
- Vascular Biology
- Stem Cell Therapy
Background:
- Critical lower-limb ischaemia (CLLI) presents significant risks, including limb loss and mortality, often unresponsive to conventional treatments.
- The core pathology of CLLI involves a critical mismatch between tissue oxygen supply and metabolic demand.
- Current therapeutic options for CLLI are frequently limited in efficacy or applicability.
Purpose of the Study:
- To review the current understanding of bone marrow stem cells (BMSCs) biology in the context of regenerative medicine.
- To assess the safety profile of cell therapy (CT) for treating critical lower-limb ischaemia.
- To evaluate the efficacy of CT utilizing BMSCs in managing CLLI.
Main Methods:
- Review of existing scientific literature on BMSC biology and their application in CLLI.
- Analysis of safety data from clinical studies involving cell therapy for critical lower-limb ischaemia.
- Synthesis of reported outcomes from studies investigating BMSC-based treatments for CLLI.
Main Results:
- Bone marrow stem cells (BMSCs) offer a promising strategy for stimulating neovascularization and promoting molecular-cellular repair in ischaemic tissues.
- Accumulated evidence suggests that cell therapy (CT) using BMSCs is relatively safe for treating critical lower-limb ischaemia.
- Variability in study outcomes is attributed to differences in CT protocols and application methods.
Conclusions:
- Cell therapy with bone marrow stem cells (BMSCs) represents a novel and potentially effective therapeutic approach for critical lower-limb ischaemia (CLLI).
- Further research is warranted to optimize CT protocols and standardize application methods to maximize treatment efficacy for CLLI.
- BMSC-based regenerative medicine holds significant promise for improving outcomes and quality of life in patients with critical lower-limb ischaemia.
Abstract:
Critical lower-limb ischaemia (CLLI) is associated with high risk of limb loss and a lethal outcome, as well as with decreased quality of life. The underlying cause of the disease is imbalance between blood supply of ischaemized tissues and their metabolic demands. Restoration of adequate perfusion with the help of standard medicamentous therapy or operative treatment is often inefficient or impossible. Cell therapy (CT) is a novel strategy making it possible to stimulate the growth of the microvascular bed and the mechanisms of molecular-cellular repair. One of the most promising trends is the use of bone marrow stem cells (BMSCs). Sufficient evidence concerning safety and relative efficacy of CT has by now been accumulated. The existing differences in the results of studies are related to numerous peculiarities of both CT itself and methods of its application. The present review is dedicated to contemporary notions of the biology of BMSCs, assessment of safety of CT and the results of its application in treatment of CLLI.
Related Concept Videos
Clinical Applications of Epidermal Stem Cells
Bones of the Upper Limb: Ulna
Bones of the Upper Limb: Radius
The radius has a nail-shaped head, and a...
Bones of the Lower Limb: Tibia and Fibula
Bones of the Upper Limb: Humerus
Bones of the Lower Limb: Femur and Patella

